Allogeneic hematopoietic SCT with reduced-intensity conditioning (RIC-HSCT) is increasingly adopted for the treatment of older adults with AML. Our goal was to verify for the first time, if center experience influences outcome of RIC-HSCT. Results of 1413 transplantations from HLA-matched related or unrelated donors for adult patients with AML in first CR were analyzed according to the level of center activity. Transplants were performed in 203 European centers between 2001 and 2007. The 2-year probability of leukemia-free survival (LFS) after RIC-HSCT performed in centers with the lowest activity (p15 procedures/7 years) was 43 ± 3% compared with 55 ± 2% in the remainder (Po0.001). The incidence of non-relapse mortality (NRM) was 24 ± 3% and 15 ± 1% (P ¼ 0.004), whilst relapse rate was 33±3% and 31±1% (P ¼ 0.33), respectively. In a multivariate model, adjusted for other prognostic factors, low RIC-HSCT activity was associated with decreased chance of LFS (hazard ratio (HR) ¼ 0.64; Po0.001) and increased risk of NRM (HR ¼ 1.47, P ¼ 0.04) and relapse (HR ¼ 1.41, P ¼ 0.01). Center experience is a very important predictor of outcome and should be considered in future analyses evaluating the results of RIC-HSCT. The reasons why centers with low RIC-HSCT activity have worse outcomes should be further investigated.
INTRODUCTION
The outcome of allogeneic hematopoietic SCT (allo-HSCT) depends on many variables related to the disease, patient, donor and procedure characteristics. However, even if all known risk factors are taken into account, transplant outcome remains highly variable, implying a role for other external factors such as the center experience, socio-economic status of a country or implementation of an international system accreditation of a transplant center. [1] [2] [3] [4] The introduction of allo-HSCT with reduced-intensity conditioning (RIC-HSCT) has allowed application of transplantation procedures to patients with advanced age and significant comorbidities. [5] [6] [7] [8] This option appears particularly important for diseases with prevalence in the elderly, like AML. [9] [10] [11] Although the proportion of RIC-HSCT among allo-HSCT is continuously growing, 12, 13 no randomized trials have been conducted to establish evidence-based standards of care. A large heterogeneity of the procedure exists with regard to the indications, conditioning regimens and protocols of immunosuppression. 14 Furthermore, the procedure requires careful monitoring of the disease status and engraftment, which may be achieved with various laboratory techniques. Long-term post-transplant care is essential as life-threatening immune-dependent complications may occur late after RIC-HSCT.
Taking into account the complexity and the heterogeneity of the procedure we evaluated whether transplant center experience affects outcome of RIC-HSCT.
PATIENTS AND METHODS

Study design and data collection
This was a retrospective multicenter analysis. Data were provided by the registry of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Centers participating in the European Group for Blood and Marrow Transplantation are annually requested to report all consecutive SCTs and follow-up. The validation and quality control program includes verification of the computer print-out of the entered data, cross-checking with the national registries, and annual on-site visits of selected teams.
Criteria of selection
Inclusion criteria were as follows: (1) patients with AML in first CR1, excluding AML secondary to myelodysplastic syndrome (2) age X18 years, (3) HSCT from HLA-identical sibling (that is, compatible for HLA-A, -B and -DRB1, as analyzed using either serological or molecular techniques) or from HLA-matched unrelated donor (82% of patients/donors of were reported to be compatible for HLA-A, -B, -C, -DRB1 and -DQB1 that is, 10 out of 10 loci; 10% were matched for 8/8 loci; 8% were matched for 6/6 loci), (4) 
Statistical analysis
The probabilities of leukemia-free survival (LFS), relapse incidence (RI), and non-relapse mortality (NRM) were the primary study end-points. The LFS was defined as time interval from RIC-HSCT to either relapse or death in remission, and was calculated using the Kaplan-Meier estimate. The RI and NRM were calculated using cumulative incidence curves in a competing risks setting, death in remission being treated as an event competing with relapse. 15, 16 Univariate analyses were done with the use of the log-rank test for LFS and Gray's test for RI and NRM.
The number of RIC-HSCT for any indication and the total number of allo-HSCT performed in the study period were used as independent variables to test the impact of center experience on outcomes. All centers were first categorized using the quintiles with increasing number of transplantation procedures. If the relative event rates in two or more adjacent categories were not substantially different, the categories were merged. Multivariate analysis was performed with the use of the Cox proportional hazard model, adjusted for potential recipient-, donor-and procedure-related risk factors, including the Human Development Index of a country where the transplantation was performed and the year of first RIC-HSCT preformed in a center.
The median follow-up for survivors was 35 months (0.4-103 months). All P-values are two-sided with type 1 error rate fixed at 0.05.
RESULTS
Leukemia-free survival
The probability of LFS in the whole group was 52% (s.e., ±1%) at 2 years. For five consecutive groups of centers with increasing number of RIC-HSCT performed between 2001 and 2007 the LFS rates were 43 ± 3, 53 ± 3, 54 ± 3, 53 ± 3 and 60 ± 1% (Table 2) . When 100 centers belonging to the first quintile (p15 RIC-HSCT in 7-year period) were compared with 103 remaining ones the difference was statistically significant (43 ± 3 versus 53 ± 2%, Po0.001) (Table 2, Figure 1 ). In contrast, no significant differences were found between centers belonging to the 2nd, 3rd, 4th, and 5th quintile. In a subgroup analysis the negative effect of low RIC-HSCT activity on LFS was particularly pronounced among patients aged 55 years or more (34±5% for the 1st quintile compared with 53±2% for 2nd-5th quintile, P ¼ 0.001) with only a tendency among younger patients (50 ± 4 versus 57 ± 2%, P ¼ 0.06). The effect could be demonstrated for transplantations from sibling (43±4 versus 57±2%, Po0.001) but not from unrelated donors (40±9 versus 49±3%, P ¼ 0.33).
In a multivariate model, the lowest activity with regard to RIC-HSCT was associated with decreased chance of LFS (hazard ratio, (HR) ¼ 0.64, 95% confidence interval ¼ 0.52-0.8, Po0.001) ( Table 2 ). Other factors associated with impaired outcome were transplantation from unrelated donor (P ¼ 0.04), the use of TBI-based conditioning (P ¼ 0.04) and recipient age 455 years (P ¼ 0.05). The chance of LFS was improved with increasing values of the Human Development Index, analyzed as a continuous variable (P ¼ 0.005).
The effect of center experience was also analyzed according to the total number of allo-HSCT performed in a study period. In this case, after categorization by quintiles, no clear cutoff point could be determined with the probabilities of LFS at 2 years for the consecutive groups of centers being 45 ± 3, 51 ± 3, 55 ± 3, 57 ± 3 and 46±4%.
Relapse incidence
The cumulative incidence of relapse in the whole study population was 31±1% at 2 years. For the five quintiles with increasing Center experience and results of RIC-HSCT S Giebel et al activity regarding RIC-HSCT, the RI was 33 ± 3%, 33 ± 3%, 34 ± 3%, 30±3% and 25±3%, respectively (Table 2) . In a univariate analysis, no significant difference could be demonstrated between centers with the lowest activity and the remaining ones (33 ± 3% versus 31±1%, P ¼ 0.33). However, in a multivariate model adjusted for other potential risk factors, transplants performed in centers with the lowest activity were associated with increased risk of relapse (HR ¼ 1.37, 95% confidence interval ¼ 1.08-1.75, P ¼ 0.01) ( Table 2 ). The only other variable affecting the risk of relapse was the use of BM as a source of stem cells (P ¼ 0.002).
The number of allo-HSCT performed between 2001 and 2007 had no significant influence on the RI with the probabilities of 34±3, 33±3, 29±3, 27±3 and 32±3% for the consecutive groups of centers with increasing number of transplantations.
Non-relapse mortality In the whole study cohort the cumulative incidence of NRM was 16 ± 1% at 2 years. For the five consecutive groups of centers with increasing number of RIC-HSCT performed between 2001 and 2007 the probability of NRM was 24±3, 13±2, 13±2, 17±1 and 15 ± 1% ( Table 2 ). The cumulative incidence of NRM was significantly higher in centers with the lowest activity compared with the remaining ones (24±3% versus 15±1%, P ¼ 0.004) (Table 2, Figure 1) . In a multivariate model, the lowest activity with regard to RIC-HSCT was associated with increased risk of NRM (HR ¼ 1.47, 95% confidence interval ¼ 1.02-2.08, P ¼ 0.04), together with TBI-based conditioning (P ¼ 0.002) ( Table 2) .
The most frequent reason of NRM was GVHD, which attributed to 43% of transplantation-related deaths in centers with the lowest RIC-HSCT activity and 39% in the remaining ones (P ¼ 0.56). The incidence of grade II-IV acute GVHD (22% versus 20%, P ¼ 0.6) and grade III-IV acute GVHD (10% versus 7%, P ¼ 0.09), as well as the probability of chronic GVHD (46±4 versus 51±2%, P ¼ 0.5) did not differ in the two respective cohorts. Infections as a cause of NRM were reported in 34% and 36% (P ¼ 0.56), respectively. Other causes, including interstitial pneumonitis, hemorrhage, cardiac toxicity and second malignancy were rare, not exceeding 5%. The incidence of primary graft failure was 2% in both the groups while the incidence of secondary graft failure was 1% in centers with the lowest activity and 0.3% in the remaining ones (P ¼ 0.19).
In the analysis according to the total number of allo-HSCT, the cumulative incidence of NRM for the 1st-5th quintile was 21 ± 3, 15±2, 16±2, 16±2 and 14±2%.
DISCUSSION
Results of allo-HSCT vary among centers. The existence of center effects with regard to LFS and NRM has been reported by Frassoni 
2).
Center experience and results of RIC-HSCT S Giebel et al et al. 1 However, in this analysis the authors failed to determine the reasons why results obtained in participating centers differed. Considerations included the possible impact of variations regarding patients' selection and details of the transplantation procedure. Subsequent studies confirmed that such variations exist and may affect outcomes. Based on internet questionnaires, Lee et al. 17 clearly showed that in the field of HSCT clinical practice varied strongly among centers and individual physicians, with regard to both indications for allo-HSCT and the choice of conditioning intensity. In another study the same group of authors demonstrated great heterogeneity related to post-transplant monitoring and supportive care, including the use of hematopoietic growth factors, empiric antibiotic therapy and protective isolation procedures. 18 Loberiza et al. 19 highlighted the importance of organizational aspects such as the number of patients-per-physician, availability of physicians after office hours and the presence of students/residents without fellows, showing not only differences among centers but also their impact on the outcome of HLA-identical sibling HSCT. With regard to the effect of center experience, Horowitz et al. 2 found increased NRM and decreased LFS for 21 centers performing p5 procedures per year compared with the remaining 65 teams, with borderline significance in a univariate analysis. On the other hand, in a French study including 35 transplant centers, the allo-HSCT activity did not influence outcome. 20 Finally, in a Japanese population the center experience influenced survival after HSCT from sibling but not from unrelated donors. 21 The role of center experience has not been previously evaluated in patients undergoing a RIC allograft. In the present study, we assumed that results of this relatively newly introduced procedure may be particularly susceptible to individual team and physician's decisions. In the absence of generally accepted standards those decisions may be in major part based on center experience. In a relatively homogenous setting of patients with AML in CR1, treated in 203 centers, we clearly demonstrated that the number of RIC-HSCT procedures performed for any indication in a study period was the most important predictor of outcome. In particular, we found that very low activity, which in our study meant 15 or less RIC-HSCT within 7 years, was associated with significantly decreased probability of LFS, resulting mainly from increased risk of NRM and to a lesser extent the risk of relapse.
The precise reasons of the above effects are difficult to identify in a retrospective analysis. With regard to relapse, the risk may depend on the disease characteristics, including cytogenetic features, the quality of CR, as well as precise monitoring of engraftment and residual disease after transplantation driving appropriate immunomodulation. The risk of NRM is mainly dependent on the recipient/donor characteristics, as well as the quality of post-transplant care. Some of these potential prognostic factors could be included in multivariate models, which proved the effect of center experience to be independent. The model was also adjusted for the socio-economic status of a country where the transplantation was performed, using the Human Development Index as a measure. In line with our previous findings, we confirmed the importance of the socio-economic status, which effect was independent on the center experience. 3 To better understand the reasons why the outcome differed between centers with very low activity and the remainder, and in particular to check if the patients preselection could be the cause, we performed additional 'post-hoc' analysis comparing transplant characteristics in centers belonging to the 1st and 2nd-5th quintile according to the RIC-HSCT activity. With the cutoff point of 15 RIC-HSCT procedures in 7 years (that is, 2.1/year) established empirically based on results of a univariate analysis, we found that the interval from diagnosis to transplantation was significantly longer for centers with low activity (median 169 days, range 53-560) compared with the remainders (median 157 days, range 28-997; P ¼ 0.002), while the interval from diagnosis to CR1 was equal: 47 days (range 14-175) and 47 days (range 10-256), respectively (P ¼ 0.73). No significant differences could be demonstrated for the recipient age (median 55 years in both cohorts), proportion of patients with adverse karyotype (20% versus 18%, respectively, P ¼ 0.56), as well as reasons for choosing RIC, which were advanced age (46 versus 45%, respectively), the presence of comorbidities (25% versus 17%, respectively), or ongoing study protocol (29% versus 38%, respectively). Importantly, the use of unrelated donors was less frequent in centers with low activity compared with the others (11% versus 29%, Center experience and results of RIC-HSCT S Giebel et al Po0.0001). The above data do not support the hypothesis that adverse patient, disease or transplant characteristics are the cause of inferior outcome in less experienced centers. It must be stressed, however, that the karyotype, being a major determinant of treatment outcome, was known in less than half of patients included in our analysis. With regard to the transplantation procedure we found significant differences including lower proportion of TBI-based conditioning (20% versus 29%, P ¼ 0.002) and BM as a source of stem cells (6% versus 10%, P ¼ 0.02) in centers with the lowest activity compared with the remainder. As both factors were found to negatively influence LFS in the Cox model, the above differences cannot explain the effect of center experience. Finally, we performed additional analysis including patients with age 55 years or more, in whom the age itself could be sufficient indication for reduction in the intensity of conditioning. In this cohort low RIC-HSCT activity was associated with 19% decrease of the 2-year probability of LFS.
Altogether it appears that the effect of center experience on outcome is not a consequence of patients' preselection. In contrast, it can be speculated that the differences in outcome are probably related to procedural details and individual physician decisions, which cannot be identified in a retrospective registry study. It must be considered, however, that the attitudes toward RIC-HSCT vary markedly in the transplantation community and in two-thirds of patients in our setting the reason for choosing RIC was not known. It is likely that the patient characteristics would differ in centers that apply this type of transplantation as the main policy compared with centers that use this treatment in few exceptional cases only. Hence, there may be confounding factors that are difficult to identify in a retrospective analysis.
In addition to the RIC-HSCT activity we also evaluated the potential influence of the total number of allo-HSCT performed in a study period. This factor, however, could not be clearly correlated with outcome. RIC-HSCT is associated with some specific requirements. In particular, detailed monitoring of chimerism with appropriate adjustment of immunosuppressive treatment is essential to prevent relapse. As well, the pattern of complications differs for RIC and myeloablative procedures. Therefore it may be that general experience with allo-HSCT cannot be easily transposed to the field of non-myeloablative transplants.
The cutoff point predictive for results of RIC-HSCT in our study was 2.1 per year. Hence, it seems that the number of procedures required to reach satisfactory results is relatively low. This should encourage the least experienced teams to increase their activity. Collaboration with centers with well-established RIC-HSCT program, including harmonization of treatment protocols, continued consultancy and education are potential tools to improve the outcome.
Finally, we postulate that the effect of center experience, as a very important predictor of outcome should be considered for future analyses evaluating the results of RIC-HSCT. Further investigation is required to determine if the impact of center experience is restricted to patients with AML.
